Compare Ginkgo Bioworks Holdings Inc (DNA) vs Zillow Group Inc Class A (ZG) Price & Performance

Ginkgo Bioworks (DNA) trades at $13.00, up 13.34% today, with a bullish technical signal from moving averages. The company shows strong gross margins of 68.04% but remains unprofitable with a -219.6% net margin. Recent news includes a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnership expansions, though revenue declined to $132M in 2026.

DNA presents high risk with significant losses and cash burn, but analyst sentiment is divided with equal buy/sell ratings. Investment appeal hinges on future profitability from recent partnerships and government contracts, while current financials and negative cash flow pose substantial downside risk.

Zillow Group (ZG) trades at $29.90, up 6.9% in the last session, showing strong momentum despite mixed technical signals. The company has demonstrated improving fundamentals with revenue growth to $2.58 billion in 2025 and a return to profitability with net income of $23 million. Recent earnings beats in Q1 and Q2 2026 suggest operational improvement, though cash flow trends remain volatile with negative net cash flow of $312 million in 2025.

The stock presents a compelling turnaround story with improving profitability and strong analyst price targets averaging $48.87, offering significant upside potential. However, investors face risks from the volatile housing market, high P/E ratio of 130, and ongoing competitive pressures in the real estate technology sector that could challenge future growth.